Australia’s largest biotech, CSL Limited (ASX:CSL), delivered stronger-than-expected full-year results, but investors were rattled by a sweeping overhaul that includes thousands of job cuts, a major spin-off and hefty one-off charges.
Following the Tuesday announcement, shares in the company were more than 16% lower by 3:45 pm AEST, erasing roughly $19 billion in market value despite a solid profit beat.
Earnings rise on plasma and Vifor strength
Underlying net profit for FY2025 rose 14% to US$3.3 billion (A$5.1 billion), supported by ongoing growth in plasma therapies at CSL Behring and contributions from the Vifor iron-deficiency business.
Revenue also came in ahead of expectations at $15.6 billion, up 5% on the previous financial year, reflecting strong global demand across key therapeutic lines. Analysts noted that on a pure earnings basis, the result underscored CSL’s resilience and its ability to generate consistent cash flow in challenging conditions.
Job cuts and Seqirus spin-off
The positive earnings were overshadowed by CSL’s most significant restructuring in decades. Management confirmed plans to cut about 3,000 jobs globally — roughly 15% of its workforce — and to close 22 underperforming plasma centres.
The shake-up also includes a planned demerger of Seqirus, the influenza vaccine arm, into a separately listed ASX company by 2026. Management argued the move will allow each division to pursue growth strategies more effectively.
Restructuring costs are expected to total between US$560–770 million, with anticipated annual savings of US$500–550 million once the program is complete. CSL said it would redirect the savings into “high-priority growth opportunities”.
Market reaction and analyst views
Investors responded sharply to the overhaul, with CSL shares tumbling more than 16% since the announcement — their steepest fall in years — and erasing about $19 billion in market value. The scale of the drop reflects concerns about execution risk and the large one-off costs tied to the restructure.
Analysts broadly agreed the underlying earnings were solid, but said markets are wary when companies embark on major transformation programs. While the cost savings and spin-off of Seqirus could create value over the longer term, the immediate uncertainty has overshadowed the profit beat and weighed heavily on sentiment.
Long-term questions
For shareholders, the message is mixed. CSL continues to post reliable profit growth and remains one of the ASX’s most defensive large caps, yet its transformation agenda introduces new execution risks.
The coming year will test whether CSL can deliver on its cost-saving targets and successfully separate Seqirus, while keeping its core plasma and therapeutics businesses growing.